BPL-003

DRUG4 trials

Sponsors

Beckley Psytech Limited

Conditions

Alcohol Use DisorderPharmacokinetics in Healthy AdultsTreatment Resistant Depression

Phase 1

Single Ascending Dose Study With BPL-003 in Healthy Subjects

CompletedNCT05347849

Beckley Psytech LimitedPharmacokinetics in Healthy Adults

Start: 2022-02-14End: 2024-01-19Updated: 2024-03-18

Phase 2

An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression

RecruitingNCT05660642

Beckley Psytech LimitedTreatment Resistant Depression

Start: 2023-02-10End: 2026-11-01Target: 72Updated: 2026-07-06

An Open-Label, Single Dose Study in Patients With Alcohol Use Disorder

CompletedNCT05674929

Beckley Psytech LimitedAlcohol Use Disorder

Start: 2023-05-30End: 2024-10-02Updated: 2026-05-22

BPL-003 Efficacy and Safety in Treatment Resistant Depression

CompletedNCT05870540

Beckley Psytech LimitedTreatment Resistant Depression

Start: 2023-09-14End: 2025-07-03Updated: 2026-09-10

Related Papers

Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-<i>N,N</i>-dimethyltryptamine benzoate) in healthy participants

Journal of Psychopharmacology2024-04-1420 citations